关于第五届董事会第十八次临时会议相关事项的独立董事意见 迪瑞医疗科技股份有限公司（以下简称"公司"）第五届董事会第十八次临 时会议于 2023 年 9 月 8 日在公司会议室召开，作为公司的独立董事，根据《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》以及《公司章程》等有关规定，本着对公司、 全体股东和投资者负责的态度，基于独立判断立场，我们对公司第五届董事会第 十八次临时会议中相关事项发表如下独立意见： 迪瑞医疗科技股份有限公司 三、关于开展远期外汇交易业务的独立意见 经核查，公司及控股子公司开展外汇衍生品交易业务以正常生产经营为基础， 主要是为了有效控制汇率大幅波动对公司经营业绩造成的不利影响，有利于加强 对外汇风险管理和控制。同时，公司按照相关法律法规的规定制定了相关管理制 度，建立健全审批程序和风险控制体系。公司开展外汇衍生品交易业务，不存在 损害公司和股东，尤其是中小股东利益的情形，相关审批程序符合法律法规以及 公司章程的规定。因此，全体独立董事同意公司及控股子公司开展远期外汇交易 业务。 （本页无正文，为《迪瑞医疗科技股份有限公司第五 ...

证券代码：300396 证券简称：迪瑞医疗 公告编号：2023-072 迪瑞医疗科技股份有限公司 关于回购注销 2022 年限制性股票激励计划部分激励对象已获授 但尚未解除限售的限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、限制性股票回购数量：132,547 股，占公司目前总股本的 0.05%。 2、2022 年限制性股票激励计划回购价格：根据公司《2022 年限制性股票激 励计划》的规定及公司第五届董事会第八次会议及第五届监事会第八次会议通过 了《关于调整 2022 年限制性股票激励计划回购价格的议案》等相关议案，本次 限制性股票的回购价格为：7.36 元/股。 3、回购注销部分限制性股票尚需通过公司股东大会审议通过后实施。 2、2022 年 8 月 10 日，迪瑞医疗召开第五届监事会第六次会议审议通过了 《关于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于公 司<2022 年限制性股票激励计划实施考核管理办法>的议案》《关于核实公司 <2022 年限制性股票激励计划首次授予激励对象名单>核查意见 ...

证券代码：300396 证券简称：迪瑞医疗 迪瑞医疗科技股份有限公司 投资者关系活动记录表 编号：2023-005 投资者关系活 √特定对象调研 □分析师会议 动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 √其他 电话会议 | --- | --- | --- | --- | |----------------|--------------|--------------|--------------| | Point72 | QIANYI | Valliance | 安信基金 | | 保银资管 | 北京宏道 | 北京金柏镕 | 北京源峰 | | 北京源乐晟 | 北京致顺 | 博道基金 | 博裕资本 | | 渤海人寿 | 财通证券 | 晨壹基金 | 成都火星资管 | | 淡水泉投资 | 德邦基金管 | 德邦证券 | 东北证券 | | 东方阿尔法基金 | 东方基金 | 东方养老 | 东方证券 | | 东方证券资管 | 东海证券 | 东吴基金 | 东吴证券 | | 东兴证券 | 东证融汇证券 | 对外济贸信托 | 沣京资管 | | 蜂巢基金 | 富国基金 | 高竹私募 | 歌斐诺宝 | | ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥694,934,022.13, representing a 34.99% increase compared to ¥514,804,515.68 in the same period last year[22]. - The net profit attributable to shareholders was ¥161,817,683.71, up 22.02% from ¥132,617,507.94 year-on-year[22]. - The net cash flow from operating activities reached ¥65,887,508.33, a significant increase of 6,519.79% compared to a negative cash flow of ¥1,026,318.30 in the previous year[22]. - Basic earnings per share rose to ¥0.5895, reflecting a 21.20% increase from ¥0.4864 in the same period last year[22]. - Total assets at the end of the reporting period were ¥2,954,527,472.52, a 1.00% increase from ¥2,925,260,842.41 at the end of the previous year[22]. - The company's net assets attributable to shareholders increased by 2.45% to ¥1,966,812,324.34 from ¥1,919,777,945.59 at the end of the previous year[22]. - The gross margin for the first half of 2023 was reported at 60%, reflecting improved operational efficiencies[51]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2023, representing a year-over-year growth of 25%[53]. - The company reported a total revenue of 3,097 million yuan for the first half of 2023, representing a 7.46% increase compared to the previous period[141]. Market Strategy and Expansion - The company aims to increase market share in major hospitals by focusing on large clients and diversifying its product offerings[32]. - The company has established a sales and service network in over 120 countries, enhancing international market presence[39]. - The company is focusing on expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[48]. - The company is exploring potential acquisitions to strengthen its product portfolio and enhance technological capabilities[48]. - The company is actively pursuing market expansion strategies to increase its footprint in both domestic and international markets[57]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2024[54]. - The company is focusing on a market-driven R&D mechanism, transitioning its product system towards intelligence and integration[69]. Research and Development - The company focuses on self-research and technological innovation, with all instrument products possessing independent intellectual property rights[32]. - The company is investing in management and talent development through the integration of the CR Group's 6S management system[41]. - The company is focusing on R&D for advanced diagnostic technologies, aiming to introduce at least five new products by the end of 2024[48]. - The company has a strong pipeline of products in various stages of regulatory approval, indicating a robust future growth potential[60]. - The company is committed to expanding its research and development efforts in the field of clinical diagnostics, as evidenced by the variety of new products in the pipeline[55]. - The company is actively pursuing regulatory approvals to ensure compliance and market readiness for its new testing products[55]. - The company is focusing on the development of nucleic acid extraction instruments, which will support clinical sample analysis and purification processes[58]. Product Development and Innovation - The company has received regulatory approval for multiple diagnostic kits, including CA19-9 and CEA, aimed at monitoring cancer patients' disease progression[44]. - The company is committed to expanding its product offerings in the oncology diagnostics market[44]. - The company is expanding its product line with new testing kits for various biomarkers, enhancing its market presence in the medical diagnostics sector[57]. - The company has introduced a fully automated sample processing system, which is expected to improve efficiency in clinical testing operations[58]. - The company is focusing on the development of immunoassay kits for various biomarkers, including β2-microglobulin and 17α-hydroxyprogesterone, with registration expected by September 9, 2024[55]. - The company has made significant advancements in the approval of its medical devices, with multiple products receiving Class II registration[55]. - The company is enhancing its market presence through the introduction of specialized protein control serums, with a registration date set for September 26, 2024[55]. Financial Management and Investments - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[4]. - The company has implemented new strategies to improve operational efficiency, aiming for a 5% reduction in costs by the end of 2023[48]. - The company reported a significant increase in user data, with a 20% growth in the number of tests conducted year-over-year[48]. - The company has invested 100 million RMB in R&D for new technologies aimed at improving diagnostic accuracy and efficiency[51]. - The company has received CNY 8,210,253.41 in tax refunds, compared to CNY 2,401,033.59 in the previous year, indicating improved cash inflow from tax returns[195]. - The company paid CNY 136,498,758.29 in dividends and interest, an increase from CNY 105,774,600.00 in the same period last year, reflecting a commitment to shareholder returns[196]. - The company is addressing talent retention and cash flow risks as it scales, emphasizing the importance of maintaining a skilled workforce and effective credit management[106]. Regulatory Compliance and Risk Management - The company is facing regulatory and policy risks in the medical device industry, which is highly influenced by government policies and industry standards, potentially impacting operations if adjustments are not made[98]. - The company emphasizes the importance of new product development and technological innovation, acknowledging the high costs and risks associated with R&D in the medical device industry[101]. - The company has implemented a strict quality management system, achieving ISO9001 and ISO13485 certifications, with many products also receiving CE and FDA approvals[70]. - The company is actively monitoring market conditions and is prepared to adjust its strategies as necessary to maintain growth and stability[141]. - The company has not encountered any objections regarding the proposed incentive plan from the supervisory board[114]. - The company has not reported any significant litigation or arbitration matters during the reporting period[138]. Shareholder and Management Changes - The company appointed a new director and financial director, enhancing its management team[113]. - The company completed the grant registration of 1.797 million restricted stocks under the 2021 incentive plan[116]. - The company reduced its total share capital from 276,030,000 shares to 275,894,600 shares due to the repurchase and cancellation of 135,400 shares[116]. - The company’s board approved adjustments to the repurchase prices for both the 2021 and 2022 restricted stock incentive plans[122]. - The company’s controlling shareholder and actual controller did not change during the reporting period[172]. - The total number of shares held by the board members and senior management at the end of the reporting period was 18,024,700 shares, after a reduction of 5,455,650 shares[171].

证券代码：300396 证券简称：迪瑞医疗 公告编号：2023-064 迪瑞医疗科技股份有限公司 关于举行网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 24 日在 巨潮资讯网上发布了公司《2023 年半年度报告》及其摘要。 为使广大投资者了解公司生产经营情况，公司拟于 2023 年 8 月 31 日（星期 四）15：00 至 17：00 采取网络远程的方式举办业绩说明会，就投资者普遍关注 的问题进行交流和沟通，具体事项通知如下： 1、时间：2023 年 8 月 31 日（星期四）15：00 至 17：00； 2、参与方式：投资者可登陆深圳证券交易所"互动易"平台"云访谈"栏 目（http://irm.cninfo.com.cn）参与本次业绩说明会。 为充分尊重投资者、提升交流的针对性，现就公司本次交流会提前向投资者 公开征集问题。投资者可提前登录"互动易"平台（irm.cninfo.com.cn）"云访谈" 栏目进入公司本次业绩说明会页面进行提问，公司将在本次业绩说 ...

迪瑞医疗科技股份有限公司 证券代码：300396 证券简称：迪瑞医疗 公告编号：2023-053 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）于2023年05月09日召开的 2022年年度股东大会审议通过了《关于回购注销2021年限制性股票激励计划部分 激励对象已获授但尚未解除限售的限制性股票的议案》《关于回购注销2022年限 制性股票激励计划部分激励对象已获授但尚未解除限售的限制性股票的议案》 《关于减少公司注册资本的议案》等议案。2023年07月07日，公司披露了《关于 部分限制性股票回购注销完成的公告》。具体内容详见公司披露于巨潮资讯网 （www.cninfo.com.cn）上的相关公告。 近日，公司完成了注册资本变更等相关的工商变更登记工作，并取得由长春 市市场监督管理局长春新区分局换发的《营业执照》。 《营业执照》登记的相关信息如下： 注册号：91220101605902656F 名称：迪瑞医疗科技股份有限公司 特此公告。 迪瑞医疗科技股份有限公司董事会 法定代表人：王学敏 ...

迪瑞医疗科技股份有限公司 关于持股 5%以上股东减持股份计划减持时间过半的公告 证券代码：300396 证券简称：迪瑞医疗 公告编号：2023-052 持股 5%以上的广东恒健国际投资有限公司保证向本公司提供的信息内 容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。 迪瑞医疗科技股份有限公司（以下简称"公司"） 于 2023 年 6 月 2 日披露 了《关于持股 5%以上股东减持股份预披露公告》。"公司持股 5%以上股东广东恒 健国际投资有限公司（以下简称"恒健国际"）计划以竞价方式减持公司股份合 计不超过 2,752,083 股，减持股份数量不超过公司总股本 1%，自本减持计划公 告之日起十五个交易日后的三个月内实施。" （以下简称"本次减持计划"） 公司接到持股 5%以上股东恒健国际的通知，截至目前，恒健国际本次减持 计划减持时间已过半，根据《上市公司股东、董监高减持股份的若干规定》《深 圳证券交易所上市公司股东及董事、监事、高级管理人员减持股份实施细则》等 相关规定，现将上述股东拟减持股份进展情况公告如下： 一、 股东减持情况 ...

迪瑞医疗科技股份有限公司（以下简称"公司"）于近日收到第五届董事会 董事黄晓光先生的辞职报告，其因工作调整原因辞去公司董事及审计委员会委员 职务。黄晓光先生的辞职不会导致公司董事会人数低于法定最低人数，不会影响 公司董事会的正常运作，黄晓光先生关于辞去公司董事的辞职报告自送达董事会 之日起生效。黄晓光先生辞职后将不在公司任职。 黄晓光先生担任的董事职务原定任期为第五届董事会届满之日（2023 年 12 月 27 日）止。截至公告披露日，黄晓光先生未持有公司股份，其将继续遵守《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所上市公司股东及董事、监 事、高级管理人员减持股份实施细则》等法律法规和业务规则中关于持有公司股 份的相关规定及其所作的相关承诺。 公司董事会对黄晓光先生在担任公司董事期间为公司发展做出的贡献表示 衷心的感谢！ 特此公告。 证券代码：300396 证券简称：迪瑞医疗 公告编号：2023-051 迪瑞医疗科技股份有限公司 关于公司董事辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、 ...

证券代码：300396 证券简称：迪瑞医疗 迪瑞医疗科技股份有限公司 投资者关系活动记录表 编号：2023-004 投资者关系活 √特定对象调研 □分析师会议 动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 √其他 电话会议 | --- | --- | --- | --- | |------------|--------------|------------|--------------| | 安信基金 | 北京润晖 | 博迈基金 | 博时基金 | | 财通基金 | 丹羿投资 | 德邦证券 | 德邦资管 | | 东北证券 | 东方基金 | 东方证券 | 东莞证券资管 | | 东吴基金 | 东亚前海 | 东证资管 | 富国基金 | | 歌斐诺宝 | 工银瑞信 | 观澜湖投资 | 光大保德信 | | 光大资管 | 广发基金 | 国海证券 | 国华兴益 | | 国泰君安 | 国泰君安资管 | 国投资管 | 国信证券 | | 海创百川 | 海富通基金 | 恒越基金 | 横越基金 | | 弘尚资管 | 弘毅远方 | 红土基金 | 泓澄投资 | | 华安基金 | 华宝基金 | 华创证券 | 华创资 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,220,007,787.71, representing a 34.69% increase compared to ¥905,795,040.28 in 2021[20]. - The net profit attributable to shareholders for 2022 was ¥261,723,955.32, a 24.66% increase from ¥209,948,414.77 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥248,983,421.75, up 32.68% from ¥187,658,243.93 in 2021[20]. - The basic earnings per share for 2022 was ¥0.96, an increase of 26.32% from ¥0.76 in 2021[20]. - The total assets at the end of 2022 amounted to ¥2,925,260,842.41, a 23.14% increase from ¥2,375,626,201.07 at the end of 2021[20]. - The net assets attributable to shareholders at the end of 2022 were ¥1,919,777,945.59, reflecting a 2.31% increase from ¥1,876,348,953.10 in 2021[20]. - The cash flow from operating activities for 2022 was ¥40,924,699.36, a significant decrease of 75.55% compared to ¥167,412,927.13 in 2021[20]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[48]. - The gross margin improved to 45%, up from 40% in the previous year, indicating better cost management and pricing strategies[48]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2022, representing a year-over-year growth of 20%[161]. Market Expansion and Strategy - The company is focusing on technological upgrades and market expansion as part of its "14th Five-Year Plan" strategy to enhance healthcare levels in China[32]. - The company is positioned to benefit from government policies aimed at enhancing healthcare infrastructure and increasing procurement demand for medical devices[31]. - The company has established a sales and service network in over 120 countries and regions, enhancing its international market presence[39]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[48]. - The company is actively pursuing partnerships and collaborations to strengthen its market position and drive growth[46]. - The company aims to enhance the motivation of its management and core technical teams by optimizing the assessment system to ensure the early achievement of the "14th Five-Year" strategic goals[116]. - The company plans to enhance its distribution network, aiming to increase the number of distribution partners by 30% in the next year[48]. Research and Development - The company has maintained a commitment to independent research and development, ensuring all its high-end instrument products possess independent intellectual property rights[32]. - The company has established a strong R&D team with 304 technical personnel across various fields, and has received approval to set up a post-doctoral research workstation, enhancing collaboration with academic institutions[45]. - The company invested approximately ¥114.34 million in R&D in 2022, representing 9.37% of its operating revenue[81]. - The company launched several new products, including the fully automated chemiluminescence immunoassay analyzer and the BF-7600 automated blood fluid analyzer, enhancing its high-end product offerings[80]. - The company is focusing on the development of integrated laboratory products, including the LA-60 fully automated sample processing system, which intelligently allocates sample paths to avoid congestion[42]. - The company is committed to ongoing research and development to improve the accuracy and reliability of its diagnostic products[50]. - The company is strategically positioning itself for future growth by diversifying its product offerings and enhancing its technological capabilities in medical testing[91]. Product Development and Innovation - The company has launched a total of 10 new products in 2022, including clinical chemistry quality control blood products and automatic gynecological secretion analysis systems[53]. - The company is focusing on expanding its product line with new diagnostic kits, including those for thyroid hormones and other key biomarkers, enhancing its market presence in the healthcare sector[84]. - The company has developed a comprehensive laboratory automation system to improve testing efficiency and reduce labor costs[36]. - The company is actively involved in the development of new technologies, particularly in the field of immunoassay and biochemical analysis[85]. - The company aims to leverage its new product launches to capture a larger share of the healthcare diagnostics market[84]. - The company is focused on expanding its product line with new testing kits for various biomarkers, including procalcitonin and B-type natriuretic peptide, enhancing its diagnostic capabilities[91]. Financial Management and Governance - The company has a complete independent labor and personnel management system, with no overlapping roles with controlling shareholders[139]. - The company has established a governance structure that includes a general meeting, board of directors, and supervisory board, ensuring clear responsibilities and compliance with regulations[134]. - The company has maintained a transparent information disclosure process, ensuring timely and accurate communication with investors[135]. - The company has a structured remuneration scheme for its senior management based on their roles and performance, ensuring alignment with company standards[157]. - The company is focused on maintaining compliance with relevant laws and regulations regarding remuneration and governance practices[157]. - The company has established an effective environmental management system, with no environmental accidents reported during the reporting period[192]. Challenges and Risks - The company faces risks from strict industry regulations and policies, which could adversely affect its operations if it fails to adapt to changes in domestic and export market policies[123]. - The company recognizes the risk of intensified market competition in the in vitro diagnostics sector and aims to innovate and strengthen its competitive advantages through product development and strategic partnerships[124]. - The company is enhancing its foreign exchange risk management mechanisms to address potential impacts from international market fluctuations and currency exchange rate volatility[127]. Shareholder Engagement and Dividends - The company plans to distribute a cash dividend of ¥4.8 per 10 shares (including tax) to all shareholders[3]. - The total cash dividend amount, including other methods, is RMB 182,100,446.34, which accounts for 100% of the distributable profit[172]. - The company has implemented an employee stock ownership plan and stock incentive plan, with the first phase of the 2021 stock incentive plan completed[173]. - The company has established a performance evaluation mechanism for senior management and implemented stock incentive plans to enhance corporate governance and attract talent[183].